We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » French Pathway for Off-Label Prescribing Increases Scrutiny, While Allowing Access
French Pathway for Off-Label Prescribing Increases Scrutiny, While Allowing Access
November 9, 2012
Recent measures in France will broaden risk-benefit scrutiny and expand off-label drugs use in justifiable situations, according to an opinion piece in the Oct. 4 issue of The New England Journal of Medicine.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor